Article: SangStat Announces State Formulary Wins for SangCya Oral Solution.

MENLO PARK, Calif.--(BW HealthWire)--June 10, 1999--

SangStat, The Transplant Company(R), (Nasdaq:SANG) announced today that SangCya(TM) (Cyclosporine Oral Solution, USP (MODIFIED)) has received approval for inclusion on the Illinois state formulary from the Illinois Technical Advisory Council (TAC). In an open debate SangStat defeated Novartis' attempts to prevent the automatic substitution of SangCya oral solution for Neoral oral solution in Illinois. This decision provides additional confirmation that SangCya oral solution is a cost-effective medication bioequivalent to and interchangeable with Neoral oral solution. The Illinois approval is a new addition to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!